• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
180686 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
, R# Y+ w) D% y+ F& o1 @: O
2 }: P3 H) F* t9 g; r; |! p$ V! O2 J. Q# g$ Y/ x' m" E2 B
Sub-category:
2 L. D' d; Z& w+ C  D5 EMolecular Targets
' o3 u" M: ^' p% H
0 e# {" z7 w6 i& P( U( y" _* l2 }
% A( x# g- c3 @# c6 mCategory:- O7 Q0 @1 x9 @6 [
Tumor Biology $ j7 Z- X+ l! U! u" t8 p0 S. V* A
  p# [) i$ [0 b' ~" W7 i

+ y. K; L5 T8 J0 ^% gMeeting:
% J; W& O$ t0 p8 ]$ `6 k* S! _2011 ASCO Annual Meeting
' g2 ?$ X* M& r; |/ {
" E9 L7 D' @+ r, z- m! D! H
0 u" U3 J6 p1 d! n& HSession Type and Session Title:
: s4 E+ a1 e, r7 lPoster Discussion Session, Tumor Biology
% d8 N5 W: ]6 u2 ^& V7 p/ [
* Z! d# g- Q. A. q, }. Z( |
2 |$ X& C1 |% t! NAbstract No:# H( B$ c% L& Y* I
10517 $ j5 v8 @4 m  \. @) S) R
- C1 j- n/ R5 N- J( P
4 V1 R' i- W" p# |; o: H: l1 z
Citation:9 I8 Z5 X/ c9 e( ~3 a
J Clin Oncol 29: 2011 (suppl; abstr 10517) 1 R! x. d) t/ f: B1 N: l

* n% }* ]) [3 v; e0 d* |+ l. n7 d, P/ s1 |" z0 Q3 {
Author(s):
/ _8 r  @0 h  u" R: {" d- {J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
/ D8 B( L+ {1 g  ~8 I& _# O+ `" N+ W' B1 C8 P- G/ d

, B' n  G8 {  g5 g8 k# y; Z
0 O- E# ]6 F8 P% R  OAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
# U4 D9 S! G. ?- ]2 W" M6 V
4 f9 r( c8 i6 w" i, N7 e' f! UAbstract Disclosures) O% \& Z0 B6 `( q8 ~% i

. Q1 O' E6 g. W* j" QAbstract:- M0 T. ], W' D6 V/ [

/ r7 e, d: R: }5 z' J
, U0 E% V' a" \* a! b$ g3 eBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.$ w4 a4 R" }- z- X

6 ?" O+ r1 X$ Z# M$ c/ u
) w6 ^. o) T% K# n- X# p
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 / P' q; y7 D, S0 S2 D" Y
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
  }2 z5 h" ~1 X
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
9 x; ?# v  {, O# A易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。+ l  T5 M9 p4 S4 ?0 j1 T
ALK一个指标医院要900多 ...
# [" a* c: O5 Y) z
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
/ _. ^# m) w- G4 r% t/ c) q  F& o# i+ E8 l, W
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表